Abstract
Following the report of beneficial effects of co-infection by GB virus C (GBV-C) for HIV-infected patients, we have studied synthetic GBV-C peptides and their relationship with HIV type-1. This paper reports the design and synthesis of new forms of presentation of two peptide inhibitors corresponding to the envelope proteins E1 and E2 of GBV-C, together with a study of their anti-HIV-1 activity. Homogeneous and heterogeneous multiple antigenic peptides (MAPs), lipophilic derivatizations, cyclization and peptide–gold conjugations are the chemical design strategies adopted. Our aim is to enhance the anti-viral potency of the GBV-C peptide domains. Of all the GBV-C peptide derivatives studied, peptide–gold complexes derived from the (22-39) sequence of the GBV-C E1 protein were the most active entry inhibitors. These results support the putative modulation of HIV-1 infection by the GBV-C E1 protein and open new perspectives for the development of novel peptide-derived HIV-1 entry inhibitors.
Keywords: Anti-HIV assays, cell–cell fusion assays, cyclic peptides, GBV-C, HIV-1, lipopeptides, multiple antigenic peptides, peptide–gold complexes.
Current Medicinal Chemistry
Title:HIV-1 Inhibiting Capacity of Novel Forms of Presentation of GB Virus C Peptide Domains is Enhanced by Coordination to Gold Compounds
Volume: 21 Issue: 2
Author(s): María J. Gómara, Ramona Galatola, Alejandro Gutiérrez, María C. Gimeno, José M. Gatell, Víctor Sánchez-Merino, Eloísa Yuste and Isabel Haro
Affiliation:
Keywords: Anti-HIV assays, cell–cell fusion assays, cyclic peptides, GBV-C, HIV-1, lipopeptides, multiple antigenic peptides, peptide–gold complexes.
Abstract: Following the report of beneficial effects of co-infection by GB virus C (GBV-C) for HIV-infected patients, we have studied synthetic GBV-C peptides and their relationship with HIV type-1. This paper reports the design and synthesis of new forms of presentation of two peptide inhibitors corresponding to the envelope proteins E1 and E2 of GBV-C, together with a study of their anti-HIV-1 activity. Homogeneous and heterogeneous multiple antigenic peptides (MAPs), lipophilic derivatizations, cyclization and peptide–gold conjugations are the chemical design strategies adopted. Our aim is to enhance the anti-viral potency of the GBV-C peptide domains. Of all the GBV-C peptide derivatives studied, peptide–gold complexes derived from the (22-39) sequence of the GBV-C E1 protein were the most active entry inhibitors. These results support the putative modulation of HIV-1 infection by the GBV-C E1 protein and open new perspectives for the development of novel peptide-derived HIV-1 entry inhibitors.
Export Options
About this article
Cite this article as:
Gómara J. María, Galatola Ramona, Gutiérrez Alejandro, Gimeno C. María, Gatell M. José, Sánchez-Merino Víctor, Yuste Eloísa and Haro Isabel, HIV-1 Inhibiting Capacity of Novel Forms of Presentation of GB Virus C Peptide Domains is Enhanced by Coordination to Gold Compounds, Current Medicinal Chemistry 2014; 21 (2) . https://dx.doi.org/10.2174/09298673113206660276
DOI https://dx.doi.org/10.2174/09298673113206660276 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets Early Diagnosis of AS or Other SpA - From Clinical and Radiologic Viewpoint
Current Rheumatology Reviews Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Acute Severe Colitis: Infliximab and/or Cyclosporine?
Current Drug Targets Use of Kv1.3 Blockers for Inflammatory Skin Conditions
Current Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets Post Translational Modification and Its Pathologic Association in Rheumatoid Arthritis: A Brief Perspective
Current Protein & Peptide Science Development and Validation of a Patient Reported Experience Measure (PREM) for Patients with Rheumatoid Arthritis (RA) and other Rheumatic Conditions
Current Rheumatology Reviews Biomarker Approach Towards Rheumatoid Arthritis Treatment
Current Rheumatology Reviews Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Ginsenoside Compound K Reduces Psoriasis-related Inflammation by Activation of the Glucocorticoid Receptor in Keratinocytes
Current Molecular Pharmacology An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases
Current Clinical Pharmacology A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with Guselkumab
Current Drug Safety A Systemic Review on Photodynamic Therapy: Emerging Technology with Healing Process
Current Cancer Therapy Reviews The Biology of p38 Kinase: A Central Role in Inflammation
Current Topics in Medicinal Chemistry TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Psoriatic Arthritis Experience in Saudi Arabia from the Rheumatologist and Patient Perspectives
Current Rheumatology Reviews Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition